PSYC Executes Initial Investment into The Conscious Fund
- Tech pulls Nasdaq, S&P 500 down as Treasury yields rise
- Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Oil up on tight supply, Brent crude nears $80 a barrel
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
PSYC Strengthens Its Position Within the Emerging Psychedelic Sector Through Investment Into Capital Fund
LAS VEGAS, NV, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a digital media leader within the emerging sector of medicinal psychedelics, is pleased to announce that the Company has completed an initial investment into The Conscious Fund (the “Fund”), an early-stage venture capital fund focused on the emerging sector of medicinal psychedelics.
The investment represents the first from PSYC of an intended total investment into The Conscious Fund of roughly $500,000 USD over the next four years. Furthermore, the Company contends that this investment may provide PSYC with a very unique opportunity to not only fortify its positioning within the rapidly expanding industry of medicinal psychedelics, but also promote the potential for long-term value for PSYC by connecting it directly to the impressive and diverse portfolio of psychedelic companies the Fund has established.
“Over the last twelve months, The Conscious Fund has done an impressive job of meticulously assembling one of the most inspiring portfolios of psychedelic-based companies within the industry,” said David Flores, Global Trac Solutions, Inc. CEO. “Because of the diversification and overall potential we see in their portfolio, we believe our investment into the Fund presents an exciting, value-driven, opportunity that we expect will not only contribute to the further development of our industry, but also inspire value for the shareholders of PSYC over the next several years.”
The Conscious Fund’s growing portfolio currently consists of some of the most prominent up and coming companies within the medicinal psychedelic sector including: ATAI Life Sciences, Bexson Biomedical, MagicMed Industries, and CYBIN, and many more.
"We are delighted to be working with David and PSYC,” said Henri Sant-Cassia, Co-Founding Partner for The Conscious Fund. “As the first public media company in psychedelic medicine, we see huge strategic value in their investment in The Conscious Fund, and we look forward to more firsts as the sector develops."
“Over the past couple of months, I have spoken about my intent of bringing diversification back into Global Trac Solutions and positioning the company on the most reasonable path to success and profitability possible,” said Flores. “This investment demonstrates my ongoing commitment to seeing this through while also demonstrating PSYC’s commitment of establishing itself as a true ally to the emergence of psychedelics.”
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ameriwest Lithium Awarded Lithium Clay Rights in Arizona
- TCL Celebrates 40th Anniversary Across the World
- Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!